Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and ...
EMA validates Immunome’s MAA for varegacestat, an oral, once-daily gamma secretase inhibitor to treat adults with desmoid tumours: Bothell, Washington Monday, November 2, 2026, ...
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer ...
Immunome, Inc. (Nasdaq: IMNM) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for varegacestat, an investigational oral once-daily gamma ...
Explore PBLS’s desmoid tumor potential, PEDESTAL Phase 3 progress, Wnt-driven oncology upside, and why this speculative ...
Immunome, Inc. had the European Medicines Agency validate the Marketing Authorization Application for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor for the treatment of ...
A preclinical study reports that the EGFR inhibitor osimertinib and the XPO1 inhibitor selinexor synergistically deplete ...
Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and ...
Immunome said Friday the European Medicines Agency validated its marketing application for varegacestat, an oral treatment for adults with desmoid tumors, and the regulator will now begin ...
Immunome (IMNM) news covers targeted oncology programs, varegacestat for desmoid tumors, ADC and radiotherapy pipeline updates, and stock grants. Latest IMNM news updated today, November 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results